Among the myriad challenges to researchers of specialty drugs and cell and gene therapies are the unique requirements of these new, innovative products and the burdens tied to establishing protocols for flexible, agile supply chain logistics in support of their research and development.
A glimpse into some of the facts and figures at play in the comings and goings of today's clinical research enterprise.
With a new international guidance open for public comments, stakeholders in digital, hybrid, and fully decentralized clinical trials (DCTs) may feel a growing urgency to harmonize global regulations to prevent any roadblocks to adopting the technologies necessary to achieve the benefits of this approach.
This study explored the experiences of clinical research principal investigators (PIs) in addressing diversity in clinical trials. The PI respondents, recruited through social media and professional networks, shared their insights through interviews.
Digital medicine represents a paradigm change in oncology research by harnessing technological breakthroughs to address the constraints of traditional clinical trial procedures. Researchers may collect huge amounts of patient-generated health data by adding digital tools into the clinical trial process.